[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Shamim M: Successful pregnancy outcome after fertility-sparing surgery and chemotherapy for dysgerminoma. J Pak Med Assoc; 2010 Sep;60(9):779-81
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful pregnancy outcome after fertility-sparing surgery and chemotherapy for dysgerminoma.
  • Ovarian dysgerminoma is a rare malignancy of the ovary.
  • This is a case report of a 30-year-old female, presenting with a huge ovarian mass along with multiple gallstones; she was treated by fertility-sparing excision of the mass and cholecystectomy, followed by chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dysgerminoma / therapy. Ovarian Neoplasms / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21381594.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


2. Tanaka Y, Fujiwara K, Yamauchi H, Mikami Y, Kohno I: Pregnancy in a woman with a Y chromosome after removal of an ovarian dysgerminoma. Gynecol Oncol; 2000 Dec;79(3):519-21
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy in a woman with a Y chromosome after removal of an ovarian dysgerminoma.
  • Therefore, it is recommended that patients with dysgerminoma of the ovary associated with the XY karyotype should undergo a bilateral salpingo-oophorectomy.
  • CASE: We report an extremely rare case of a true hermaphrodite with a 20% 46,XX/80% 46,XY karyotype who became pregnant after removal of an ovarian dysgerminoma.
  • A dysgerminoma with ovotestis was found in the right ovary.
  • Two courses of chemotherapy following a right salpingo-oophorectomy were carried out.
  • CONCLUSION: A unilateral salpingo-oophorectomy followed by combination chemotherapy can be the treatment of choice for any woman who wishes to preserve her capacity for conception at the time of operation for dysgerminoma of the ovary.
  • [MeSH-major] Disorders of Sex Development / genetics. Dysgerminoma / surgery. Ovarian Neoplasms / surgery. Pregnancy Complications, Neoplastic / etiology

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11104633.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


3. Ivanaj A, Pautier P, Rixe O, Duvillard P, Dubard T: Peripheral neuropathy in association with an ovarian dysgerminoma. Gynecol Oncol; 2003 Apr;89(1):168-70
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral neuropathy in association with an ovarian dysgerminoma.
  • BACKGROUND: Peripheral neuropathy among women with ovarian dysgerminoma has not been so far reported in the literature.
  • CASE: We report a case of an 18-year-old woman with an association of an abdominal relapse of an ovarian dysgerminoma and a polyradiculoneuritis.
  • The normality of neurologic investigations and the disappearance of all sensitive and muscular alterations after tumor ablation and one cycle of chemotherapy are in favor of a paraneoplastic syndrome.
  • CONCLUSION: We describe the first case of a polyradiculoneuritis associated with an ovarian dysgerminoma.
  • The evolution of the paraneoplastic syndrome was favorable after treatment of the tumor.
  • [MeSH-major] Dysgerminoma / complications. Ovarian Neoplasms / complications. Paraneoplastic Polyneuropathy / complications. Polyradiculoneuropathy / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694672.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Hubalek M, Smekal-Schindelwig C, Zeimet AG, Sergi C, Brezinka C, Mueller-Holzner E, Marth C: Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma. Arch Gynecol Obstet; 2007 Aug;276(2):179-83
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma.
  • BACKGROUND: Diagnosis of malignant ovarian tumours during pregnancy is uncommon.
  • This report presents a case of a pregnant woman with ovarian dysgerminoma.
  • CASE REPORT: At 24 weeks gestation, a 33-year-old patient was diagnosed with unilateral ovarian dysgerminoma.
  • After surgery, she received three additional cycles of chemotherapy in an adjuvant setting.
  • CONCLUSION: This case report illustrates the difficulties arising from diagnosis of malignancy during pregnancy.
  • Although combined treatment with paclitaxel and carboplatin is not considered a first-line therapy for ovarian dysgerminoma, in this case report it elicited an excellent response, and there were no adverse effects on the foetus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Ovarian Neoplasms / drug therapy. Pregnancy Complications, Neoplastic / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342499.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Takemori M, Ichimura T, Nishimura R, Hasegawa K: Ovarian dysgerminoma with massive metastases to para-aortic lymph nodes. Gynecol Obstet Invest; 2000;49(3):211-3
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian dysgerminoma with massive metastases to para-aortic lymph nodes.
  • We report on a 15-year-old female with left ovarian dysgerminoma accompanied by massive swelling of the para-aortic lymph nodes which was clearly demonstrated by preoperative magnetic resonance imaging (MRI).
  • Metastasis to the para-aortic lymph nodes from dysgerminoma was confirmed by biopsies obtained during surgery.
  • No study has previously reported dysgerminoma with massive para-aortic lymph node metastases clearly demonstrated by MRI.
  • The patient received six cycles of cisplatin-based combination chemotherapy with the BEP regimen (bleomycin, etoposide and cisplatin) after conservative surgery, and no residual para-aortic lymph nodes were detected by MRI or CT after the chemotherapy.
  • [MeSH-major] Dysgerminoma / secondary. Lymphatic Metastasis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta. Biopsy. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 10729765.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


6. Ramírez Torres N, Basavilvazo Rodríguez MA, Téllez Márquez A, Robles Robles G, Lemus Rocha R, Hernández Valencia M: [Clinical experience with chemotherapy of the malignant tumor of germinal cells (dysgerminoma) of the ovary]. Ginecol Obstet Mex; 2004 Oct;72:500-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience with chemotherapy of the malignant tumor of germinal cells (dysgerminoma) of the ovary].
  • [Transliterated title] Experiencia clínica con el tratamiento a base de quimioterapia del tumor maligno de células germinales (disgerminoma) del ovario.
  • OBJECTIVE: To evaluate two alternative plans of chemotherapy with EP (etoposide, platinum) and BEP (bleomycin, etoposide, platinum) after oncological surgery.
  • MATERIAL AND METHODS: A clinical, longitudinal and descriptive study was done, where the cases with pure dysgerminoma diagnosed in the gynecology-oncology service during the years from 1992 to 2003 were included.
  • Histological study confirmed the pure dysgerminoma, with a mean duration of the symptoms of 5.2 months, the free survival of disease was of 39.6 months and general survival was of 49.5 months.
  • It was administered early chemotherapy in 11 patients, from which 7 received EP and the other 4 received BEP.
  • There were 3 patients rescued with chemotherapy of second line and a patient with radiotherapy to central nervous system.
  • The statistical analysis showed that size of tumor among the recurrent group (24.2 cm) and the group without recurrence (14.5 cm) had significant differences (p = 0.018), the size of the tumor and the free survival of disease did not have significant correlation (p = 0.99), but upon comparing the general survival with the phase of the disease, a significant correlation was found (p = 0.03), where the survival to 5 years was observed in 6 cases (33.3%), of which a case was treated with surgery and without chemotherapy, 4 cases with EP and a case with BEP.
  • [MeSH-major] Dysgerminoma / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Longitudinal Studies. Survival Rate. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790190.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


7. Jeyakumar A, Cabeza R, Hindenburg A: Late recurrence in ovarian dysgerminoma with successful response to standard adjuvant chemotherapy: a case report and review of the literature. Gynecol Oncol; 2001 May;81(2):314-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late recurrence in ovarian dysgerminoma with successful response to standard adjuvant chemotherapy: a case report and review of the literature.
  • BACKGROUND: Ovarian dysgerminomas are quite amenable to treatment and very good cure rates are achieved even with advanced disease.
  • However, recent literature suggests that late recurrence may be associated with a poorer prognosis and bleomycin/etoposide/cisplatin (BEP) chemotherapy may play only a limited role in its management.
  • We present a patient who had a late recurrence of ovarian dysgerminoma with successful treatment outcome.
  • CASE: A 25-year-old woman was diagnosed with a stage IC ovarian dysgerminoma in 1983 and did not undergo adjuvant treatment.
  • She had late recurrence 12 years later with good treatment response to BEP chemotherapy given in a semiadjuvant fashion.
  • CONCLUSION: Our case demonstrates that BEP chemotherapy still plays an important role in treatment of late recurrence in ovarian dysgerminomas provided there is small volume disease at time of detection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dysgerminoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11330968.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  • [Number-of-references] 14
  •  go-up   go-down


8. Li YF, Li MD, Wu QL, Liu FY, Li JD, Zou JL, Huang YW: [Clinical analysis of 57 patients with ovarian dysgerminoma]. Ai Zheng; 2002 Jan;21(1):79-82
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 57 patients with ovarian dysgerminoma].
  • BACKGROUND & OBJECTIVE: Ovarian dysgerminoma is an uncommen ovarian malignancy.
  • The aim of this study is to investigate the clinical features and factors related to prognosis of ovarian dysgerminoma.
  • METHOD: The data of 57 patients with pure Ovarian Dysgerminoma were analyzed retrospectively, who were admitted to Cancer Center, Sun Yat-sen University of Medical Sciences from January 1, 1964 to December 31, 2000.
  • Combined modality was given to 52 cases and single-method treatment 5 cases.
  • Of 23 patients in stage I group to whom only chemotherapy were given after operation, 19 cases received 3 or more courses and were well being without recurrence; four patients received only one course and one of them recurred 21 months after operation.
  • In the group of stage II and III cases the 5-year survival rate was 86.7% for those whose chemotherapy courses were > or = 4 and 25.0% for patients who received less than 4 courses of chemotherapy (P < 0.05).
  • CONCLUSIONS: The prognosis of ovarian dysgerminoma is closely related to disease stage and modality of treatment.
  • [MeSH-major] Dysgerminoma / therapy. Ovarian Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12500404.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Zuntová A, Sumerauer D, Teslík L, Koutecký J: [Ovarian dysgerminoma in children and adolescents. Retrospective clinico-pathologic study]. Cas Lek Cesk; 2004;143(4):246-52
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian dysgerminoma in children and adolescents. Retrospective clinico-pathologic study].
  • BACKGROUND: To review the treatment strategy, follow up and outcome for all patients with pure ovarian dysgerminoma treated in childhood and adolescence.
  • METHODS AND RESULTS: Twenty-one patients younger than 18 years were treated between 1979-2002 in Faculty Hospital Motol for newly diagnosed pure ovarian dysgerminoma.
  • The median age at the time of diagnosis was 12.5 years (range 6 years, 5 months--17 years, 11 months).
  • All patients, except two girls with bilateral dysgerminoma, underwent unilateral adnexectomy or ovarectomy.
  • Ten girls were treated postoperatively with chemotherapy, eight with chemotherapy and radiotherapy (eleven with cisplatine based chemotherapy).
  • Three girls with dysgerminoma confined to the ovary (stage IA) have not received adjuvant chemotherapy.
  • Majority of patients does not have severe treatment sequelae, three pregnancies have occurred so far.
  • CONCLUSIONS: Most patients with dysgerminoma, including those with metastases can expect cure when treated with conservative surgery and cisplatine based chemotherapy.
  • Reduction of treatment toxicity and preservation of reproductive function is a main task.
  • The girls with dysgerminoma confined to the ovary (stage IA) can be treated with fertility sparing surgery, other should be treated with cisplatine based chemotherapy.
  • [MeSH-major] Dysgerminoma. Ovarian Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218724.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  •  go-up   go-down


10. Prado S, Yazigi R, Garrido J, Gonzalez M, Torres R, Oddo D: Recurrent ovarian dysgerminoma after laparoscopy. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:397-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent ovarian dysgerminoma after laparoscopy.
  • To our knowledge, recurrent dysgerminoma at the site of tumor removal by laparoscopy in a patient with stage IA disease has not been previously reported.
  • A woman with ovarian dysgerminoma treated by laparoscopy and tumor removed through the cul-de-sac recurred the 17 months later at the site of tumor removal.
  • She was successfully treated with etoposide, bleomycin, and cisplatin chemotherapy with complete response.
  • This case illustrates the potential for surgical site implant of an ovarian dysgerminoma; surgeons should follow strict guidelines when performing laparoscopic procedures for ovarian malignancies in order to prevent this type of incident.
  • [MeSH-major] Dysgerminoma / therapy. Gynecologic Surgical Procedures / adverse effects. Laparoscopy / adverse effects. Neoplasm Recurrence, Local. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Remission Induction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515632.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


11. Vicus D, Beiner M, Klachook S, Le L, Ginsburg O, Laframboise S, Mackay H: Dysgerminoma of the ovary 35 years on: A single institutional experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysgerminoma of the ovary 35 years on: A single institutional experience.
  • : e16523 Background: Ovarian dysgerminomas are rare but are relatively more common in women under 20 years of age in whom fertility is likely to be an issue.
  • The aim of this study was to review our institutional experience in treating patients (pts) diagnosed with pure dysgerminoma.
  • METHODS: We performed a retrospective chart review of all pts diagnosed with ovarian dysgerminoma at the Princess Margaret Hospital, Toronto, between 1970 and 2005.
  • RESULTS: 65 pts were diagnosed with ovarian dysgerminoma, median age 21.9 years (range 8.1-64.1 yrs).
  • 17 pts received chemotherapy, 15 adjuvant and 2 for residual disease (all post 1988); 8 for stage I, 1 for stage II, and 8 for stage III.
  • 1 pt received a combination of adjuvant chemotherapy and radiation.
  • 6 (9.2%) pts recurred all within 19 months of initial diagnosis.
  • Treatment of recurrent disease was by salvage surgery and chemotherapy (3 pts), radiotherapy (2 pts), and EP (1 pt).
  • All pts who recurred responded to treatment and were alive at last follow up, median follow up 22.5 yrs (range 9.3-31.4 yrs).
  • 15 pts attempted to conceive posttreatment; 6 had received adjuvant treatment; 4 EP; and 2 whole abdominal radiotherapy.
  • CONCLUSIONS: The long-term outcome of patients with an ovarian dysgerminoma is excellent.
  • Recurrences occured within 2 years of diagnosis and are treatable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Ayhan A, Bildirici I, Günalp S, Yuce K: Pure dysgerminoma of the ovary: a review of 45 well staged cases. Eur J Gynaecol Oncol; 2000;21(1):98-101
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure dysgerminoma of the ovary: a review of 45 well staged cases.
  • PURPOSE: To evaluate the significance of meticulous surgical staging, and whether type of initial surgery or adjuvant therapy impacted on survival in cases of pure ovarian dysgerminoma.
  • METHODS: Retrospective chart review of 45 patients treated for pure ovarian dysgerminoma at a single institute.
  • RESULTS: Of the 45 patients subjected to a surgical staging procedure 30 (67%) had stage I disease, 2 (4%) had stage II, 9 (20%) had stage III, and 4 (9%) had stage IV pure ovarian dysgerminoma.
  • With a median follow-up of 61 months, the overall survival rate for ovarian dysgerminoma in this series was 84%.
  • Significantly lower survival rates were found in patients with advanced stage (stage III-IV) ovarian dysgerminoma (53.9%), when compared with earlier stages (96.9%).
  • As regards recurrence or survival rate, no significant difference was found between patients who were treated conservatively or nonconservatively, whether or not adjuvant chemotherapy or radiotherapy was given.
  • CONCLUSION: After careful surgical staging and confirming unilateral disease, conservative surgery, followed if necessary by adjuvant chemotherapy, seems to be the ideal treatment in cases of pure ovarian dysgerminoma.
  • [MeSH-major] Dysgerminoma / pathology. Neoplasm Staging. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10726633.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ITALY
  •  go-up   go-down


13. Kdous M, Hachicha R, Gamoudi A, Boussen H, Benna F, Rahal K: [Pure dysgerminoma of the ovary. 12 case reports]. Tunis Med; 2003 Dec;81(12):937-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pure dysgerminoma of the ovary. 12 case reports].
  • [Transliterated title] Les dysgerminomes ovariens purs. A propos de 12 cas.
  • Data from the files of 12 patients with pur ovarian dysgerminoma managed between January 1970 and december 1990 were evaluated.
  • Pur ovarian dysgerminoma accounts for 2% of all ovarian malignancies and 28% of malignant germ cell tumors.
  • Echography objective ovarian tumor in all cases.
  • Diagnosis was histological.
  • Primary treatment was surgery followed by radiotherapy in 8 cases and chemotherapy in 2 cases.
  • 2 patients developed local recurrences were irradiated and 1 patient developed distant metastases was given chemotherapy in association to radiotherapy.
  • CONCLUSION: Treatment of ovarian dysgerminoma remains controversial.
  • For all other patients, radical surgery followed by radiation therapy or chemotherapy for the advanced stages and recurrents dysgerminoma is the treatment of choice.
  • Prospective randomized clinical trials are needed for a well codified therapeutic strategy.
  • [MeSH-major] Dysgerminoma / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Female. Humans. Infertility, Female / etiology. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14986529.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


14. Ishibashi M, Nakayama K, Oride A, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki K: [A case of PEP(BEP)-resistant ovarian dysgerminoma successfully treated by VeIP therapy]. Gan To Kagaku Ryoho; 2009 Mar;36(3):513-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of PEP(BEP)-resistant ovarian dysgerminoma successfully treated by VeIP therapy].
  • Ovarian germ cell tumors are malignant tumors which commonly develop during childhood, and which are sensitive to chemotherapy.
  • We have had a case of germ cell tumors which showed resistance to first-line PEP(BEP)chemotherapy.
  • As second-line chemotherapy, VeIP therapy was used, because it is possible that this therapy is effective against recurrent testicular germ cell tumors.
  • She experienced acute abdominal pain and visited the hospital, where she was diagnosed with torsion of an ovarian tumor.
  • An emergency laparotomy and right salpingoophorectomy were performed, the pathological diagnosis being stage Ia ovarian dysgerminoma G1.
  • An MRI revealed an abnormal signal in the left ovary, so we diagnosed this as a recurrence of the dysgerminoma.
  • Then she received chemotherapy PEP(BEP), but after eight months of PEP (BEP), her serum hCG-CTP was again elevated to 14.5 mIU/mL.
  • The recurrent region was detected in the left ovary.
  • A left ovarian cystectomy was performed in which CDDP ip was used.
  • After the operation, the patient again underwent chemotherapy.
  • After 6 courses of this therapy, she had a follow-up operation.
  • She remains without recurrence of this disease 24 months after VeIP therapy.
  • This case suggests that VeIP therapy might be an effective second-line therapy for patients with PEP(BEP)-resistant ovarian dysgerminoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / drug effects. Dysgerminoma / drug therapy. Dysgerminoma / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Positron-Emission Tomography. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295284.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Desirotte G, Pintiaux A, Foidart JM, Nisolle M: [Four clinical cases of dysgerminoma]. Rev Med Liege; 2008 Sep;63(9):523-7
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four clinical cases of dysgerminoma].
  • [Transliterated title] Le cas clinique du mois. Quatre cas de dysgerminomes.
  • Dysgerminoma is an ovarian germ cell tumor occurring more frequently among young women.
  • The efficacy of chemotherapy allows conservative surgery sparing fertility.
  • A stadification surgery will avoid chemotherapy for patients with stage Ia.
  • A ct-scan is performed twice a year and, in case of recurrence, a first or a second chemotherapy should be prescribed.
  • [MeSH-major] Dysgerminoma. Ovarian Neoplasms

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051506.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


16. Varras M, Tsikini A, Polyzos D, Samara Ch, Akrivis Ch: Internal hemorrhage caused by a twisted malignant ovarian dysgerminoma: ultrasonographic findings of a rare case and review of the literature. Clin Exp Obstet Gynecol; 2004;31(1):73-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Internal hemorrhage caused by a twisted malignant ovarian dysgerminoma: ultrasonographic findings of a rare case and review of the literature.
  • PURPOSE: Ovarian cancer presents as an acute abdomen very rarely.
  • The purpose of the study is the description of a right ovarian malignant dysgerminoma presenting as an abdominal emergency.
  • The uterus and the left ovary had normal size and echo-texture.
  • Fluid was found in the cul-de-sac and in Morisson's space.
  • An immediate exploratory laparotomy exposed the presence of a twisted right ovarian mass and intraperitoneal hemorrhage.
  • The intra-abdominal hemorrhage ceased when the ovarian pedicle was clamped.
  • Pathologic analysis revealed a malignant dysgerminoma of the right ovary, expanding to the mesosalpinx.
  • The patient was assigned to FIGO Stage IIC and referred for platinum-based chemotherapy.
  • CONCLUSION: Ovarian malignant dysgerminoma may present as an acute abdomen because of torsion, passive blood congestion, rupture of superficial tumoral vessels and subsequent intra-abdominal hemorrhage.
  • Ovarian dysgerminoma should be part of the differential diagnosis in a young woman with acute surgical abdomen and a solid heterogeneous pelvic mass detected by ultrasonographic scan.
  • [MeSH-major] Abdomen, Acute / etiology. Dysgerminoma / complications. Hemoperitoneum / etiology. Ovarian Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14998196.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Vicus D, Beiner ME, Klachook S, Le LW, Laframboise S, Mackay H: Pure dysgerminoma of the ovary 35 years on: a single institutional experience. Gynecol Oncol; 2010 Apr;117(1):23-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure dysgerminoma of the ovary 35 years on: a single institutional experience.
  • OBJECTIVE: The aim of this study was to evaluate clinicopathologic characteristics, long-term outcome and reproductive function in women diagnosed with pure dysgerminoma of the ovary.
  • METHODS: Sixty-five women with stage IA to IIIC pure ovarian dysgerminoma were identified and included in this retrospective study.
  • RESULTS: Median age at diagnosis was 22.2 years (range 8.2-64.1 years).
  • Seventeen patients received chemotherapy (15 adjuvant, 2 for residual disease), 20 received adjuvant radiotherapy and one patient received both.
  • All recurrences occurred within 19 months of primary diagnosis.
  • All patients were successfully salvaged with radiotherapy (2 patients), chemotherapy (1 patient) or a combination of surgery and chemotherapy (3 patients).
  • Overall, median follow up from time of recurrence was 22.5 years (range 9.3-31.4 years).
  • CONCLUSION: The long-term outcome of patients with pure ovarian dysgerminoma is excellent.
  • Recurrences occur within 2 years of diagnosis and are treatable.
  • [MeSH-major] Dysgerminoma / pathology. Dysgerminoma / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Disease-Free Survival. Female. Fertility. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20097412.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Mohammadianpanah M, Omidvari S, Mosalaei A, Ahmadloo N: Cisplatin-induced hypokalemic paralysis. Clin Ther; 2004 Aug;26(8):1320-3
Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Profound hypokalemic conditions resulting from cisplatin therapy have been known to produce hypokalemic paralysis in rare cases.
  • CASE SUMMARY: A 15-year-old Persian girl with ovarian dysgerminoma presented with severe generalized weakness and paraplegia 1 week after the fourth course of cisplatin-based chemotherapy.
  • DISCUSSION: Adverse drug reactions are common with cisplatin, but the drug is only rarely associated with hypokalemic paralysis.
  • This adverse drug event--whether isolated or secondary to hypomagnesemia--may be deceptive, leading to a fatal mistake in the oncology setting, and should therefore be precisely differentiated from cancer-related complications.
  • Regular serum electrolyte measurement, the early detection of cation deficiency, and appropriate replacement of cations are all recommended.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cisplatin / adverse effects. Hypokalemic Periodic Paralysis / chemically induced. Hypokalemic Periodic Paralysis / diagnosis
  • [MeSH-minor] Adolescent. Blood Chemical Analysis. Diagnosis, Differential. Dysgerminoma / drug therapy. Female. Humans. Ovarian Neoplasms / drug therapy. Potassium / administration & dosage

  • Genetic Alliance. consumer health - paralysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15476912.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; RWP5GA015D / Potassium
  •  go-up   go-down


19. Kasenda B, Harter P, Hirsch T, Ast A, Buhrmann C, Glaser F, Du Bois A: Para-aortic lymph node metastasis in malignant dysgerminoma of the ovary. Acta Obstet Gynecol Scand; 2009;88(11):1288-90
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Para-aortic lymph node metastasis in malignant dysgerminoma of the ovary.
  • Dysgerminomas comprise approximately 2-5% of all ovarian malignancies and mostly affect young adolescent women.
  • Primary comprehensive surgery and adjuvant chemotherapy consisting of bleomycin, etoposide, and cisplatin (BEP) are the current recommended treatment options, the latter reserved for advanced stages (FIGO II-IV).
  • Both were subsequently diagnosed with recurrent malignant dysgerminoma and para-aortic lymph node metastasis.
  • Neither had received comprehensive staging at initial surgery nor adjuvant radio or chemotherapy.
  • Both needed extensive surgery and multiagent chemotherapy for survival and belong to the small percentage of FIGO IA dysgerminoma patients showing a relapse.
  • Comprehensive initial surgery including systematic para-aortic lymphadenectomy and adjuvant chemotherapy at tertiary referral centers is needed to minimize the treatment burden.
  • [MeSH-major] Dysgerminoma / secondary. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Lymphatic Metastasis. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19900144.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


20. Boran N, Tulunay G, Caliskan E, Köse MF, Haberal A: Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas. Arch Gynecol Obstet; 2005 Feb;271(2):104-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy outcomes and menstrual function after fertility sparing surgery for pure ovarian dysgerminomas.
  • MATERIALS AND METHODS: The medical records of 23 patients with pure ovarian dysgerminoma treated by conservative surgery at SSK Ankara Maternity Hospital between 1991 and 2001 were reviewed retrospectively.
  • Wedge biopsy of contralateral ovary was performed in 17 patients (74%) and tumor was diagnosed in 2 (11.7%).
  • Adjuvant chemotherapy was applied in 16 (70%) of the cases.
  • The sites of recurrences were contralateral ovary in all cases.
  • Three of the primiparous patients delivered after treatment.
  • Five pregnancies occurred in 3 nulliparous patients at the time of primary surgery.
  • CONCLUSION: Fertility sparing treatments are safe in patients with pure ovarian dysgerminoma.
  • [MeSH-major] Dysgerminoma / surgery. Fertility. Menstruation. Ovarian Neoplasms / surgery. Ovariectomy / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Female. Humans. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Retrospective Studies

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Menstruation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15007601.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Rajbhandari S, Shrestha B, Karki A: Diagnostic dilemma of an unusual pelvic mass in a young girl. JNMA J Nepal Med Assoc; 2007 Oct-Dec;46(168):199-202
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dysgerminoma of ovary is the most common germ cell tumor, accounting for 50% of all germ cell tumor cases.
  • It is rare to find both ovaries to be involved in germ cell tumors.
  • The prognosis of patients with malignant germ cell has improved significantly over the last two decades after the introduction of chemotherapy specially cisplatin.
  • The only exceptions are stage 1, grade 1, immature teratoma and stage 1A dysgerminoima who are followed up after surgery without adjuvant chemotherapy.
  • Normal ovarian functions and fertility can be retained in most patients by following the conservative surgery.
  • [MeSH-major] Dysgerminoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Laparotomy. Ovariectomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340374.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


22. Tatekawa Y, Kemmotsu H, Mouri T, Joe K, Ohkawa H: A case of pediatric ovarian dysgerminoma associated with high serum levels and positive immunohistochemical staining of neuron-specific enolase. J Pediatr Surg; 2004 Sep;39(9):1437-9
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of pediatric ovarian dysgerminoma associated with high serum levels and positive immunohistochemical staining of neuron-specific enolase.
  • At operation, the main tumor arose from the left ovary and was associated with torsion, whereas the other lesions were lymph node metastases.
  • Histopathologic examination indicated that the tumor was a dysgerminoma.
  • The elevated serum levels of tumor markers improved dramatically after the operation and chemotherapy.
  • [MeSH-major] Doxorubicin / analogs & derivatives. Dysgerminoma / enzymology. Neoplasm Proteins / analysis. Ovarian Neoplasms / enzymology. Phosphopyruvate Hydratase / analysis
  • [MeSH-minor] Alkaline Phosphatase / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers. Bleomycin / administration & dosage. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carboplatin / administration & dosage. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Female. Humans. Isoenzymes / analysis. L-Lactate Dehydrogenase / blood. Ovariectomy. Torsion Abnormality / etiology. Vinblastine / administration & dosage. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15359410.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / Isoenzymes; 0 / Neoplasm Proteins; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; D58G680W0G / pirarubicin; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.1.3.1 / Alkaline Phosphatase; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down






Advertisement